167 related articles for article (PubMed ID: 33248322)
1. Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up.
Giaccone G; Kim C
J Thorac Oncol; 2021 Mar; 16(3):483-485. PubMed ID: 33248322
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.
Giaccone G; Kim C; Thompson J; McGuire C; Kallakury B; Chahine JJ; Manning M; Mogg R; Blumenschein WM; Tan MT; Subramaniam DS; Liu SV; Kaplan IM; McCutcheon JN
Lancet Oncol; 2018 Mar; 19(3):347-355. PubMed ID: 29395863
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.
Cho J; Kim HS; Ku BM; Choi YL; Cristescu R; Han J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Clin Oncol; 2019 Aug; 37(24):2162-2170. PubMed ID: 29906252
[TBL] [Abstract][Full Text] [Related]
4. Response to Pembrolizumab in a Patient with Relapsing Thymoma.
Zander T; Aebi S; Rast AC; Zander A; Winterhalder R; Brand C; Diebold J; Gautschi O
J Thorac Oncol; 2016 Dec; 11(12):e147-e149. PubMed ID: 27498287
[No Abstract] [Full Text] [Related]
5. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
Rajan A; Heery CR; Thomas A; Mammen AL; Perry S; O'Sullivan Coyne G; Guha U; Berman A; Szabo E; Madan RA; Ballester LY; Pittaluga S; Donahue RN; Tsai YT; Lepone LM; Chin K; Ginty F; Sood A; Hewitt SM; Schlom J; Hassan R; Gulley JL
J Immunother Cancer; 2019 Oct; 7(1):269. PubMed ID: 31639039
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
Leighl NB; Hellmann MD; Hui R; Carcereny E; Felip E; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Lubiniecki GM; Zhang J; Piperdi B; Garon EB
Lancet Respir Med; 2019 Apr; 7(4):347-357. PubMed ID: 30876831
[TBL] [Abstract][Full Text] [Related]
7. Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report.
Chen C; Sun P; Long J
Front Immunol; 2022; 13():941092. PubMed ID: 35983052
[TBL] [Abstract][Full Text] [Related]
8. Molecular predictors of response to pembrolizumab in thymic carcinoma.
He Y; Ramesh A; Gusev Y; Bhuvaneshwar K; Giaccone G
Cell Rep Med; 2021 Sep; 2(9):100392. PubMed ID: 34622229
[TBL] [Abstract][Full Text] [Related]
9. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.
Remon J; Girard N; Novello S; de Castro J; Bigay-Game L; Bernabé R; Greillier L; Mosquera J; Cousin S; Juan O; Sampayo M; Besse B
Clin Lung Cancer; 2022 May; 23(3):e243-e246. PubMed ID: 34393061
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
11. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
Garon EB; Hellmann MD; Rizvi NA; Carcereny E; Leighl NB; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Felip E; Goldman JW; Scalzo C; Jensen E; Kush DA; Hui R
J Clin Oncol; 2019 Oct; 37(28):2518-2527. PubMed ID: 31154919
[TBL] [Abstract][Full Text] [Related]
12. Successful pembrolizumab treatment for microsatellite instability-high thymoma: A case report.
Kaneko T; Sekine A; Komatsu S; Otoshi R; Haga S; Tagami Y; Kaneko T; Ogura T
Respir Investig; 2024 Jul; 62(4):517-519. PubMed ID: 38631274
[TBL] [Abstract][Full Text] [Related]
13. Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma.
Hyun JW; Kim GS; Kim SH; Cho JY; Kim HJ; Lee GK; Kim HJ; Kwon SU
Clin Lung Cancer; 2020 Mar; 21(2):e74-e77. PubMed ID: 31718909
[No Abstract] [Full Text] [Related]
14. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
15. The Use of Sunitinib as Maintenance Therapy in a Pediatric Patient With a Poorly Differentiated Thymic Carcinoma.
Romanos-Sirakis E; Doan A; Bittman ME; Webb RL; Williamson AK; Edelman M; Hanson D; Riely GJ; Fein Levy C
J Pediatr Hematol Oncol; 2022 Mar; 44(2):e605-e608. PubMed ID: 34486558
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma.
Gbolahan OB; Porter RF; Salter JT; Yiannoutsos C; Burns M; Chiorean EG; Loehrer PJ
J Thorac Oncol; 2018 Dec; 13(12):1940-1948. PubMed ID: 30121390
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
Tsukita Y; Inoue A; Sugawara S; Kuyama S; Nakagawa T; Harada D; Tanaka H; Watanabe K; Mori Y; Harada T; Hino T; Fujii M; Ichinose M
Lung Cancer; 2020 Jan; 139():89-93. PubMed ID: 31751805
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
